Besides, an impressive result was found, as well as in their melanoma trial [34], that robust CD4+ T-cell response against immunized neoantigens that was even higher than CD8+ T-cell response was detected, despite the use of MHC class I binding prediction algorithms. This evidence concerns the gene CD4 and melanoma.